HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Gi-Ae | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.contributor.author | An, Ji hyun | - |
dc.contributor.author | Lee, Danbi | - |
dc.contributor.author | Shim, Ju Hyun | - |
dc.contributor.author | Kim, Kang Mo | - |
dc.contributor.author | Lee, Han Chu | - |
dc.contributor.author | Chung, Young-Hwa | - |
dc.contributor.author | Lee, Yung Sang | - |
dc.contributor.author | Suh, Dong Jin | - |
dc.date.accessioned | 2022-07-16T03:34:00Z | - |
dc.date.available | 2022-07-16T03:34:00Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2014-08 | - |
dc.identifier.issn | 0017-5749 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/159321 | - |
dc.description.abstract | Objective Little is known about the long- Term clinical outcome and durability of HBsAg seroclearance following nucleos(t)ide analogue (NUC) therapy in patients with chronic hepatitis B (CHB). Design During a median follow-up period of 6 years (33 567 patient-years) of 5409 CHB patients who were initially treated with lamivudine or entecavir, a total of 110 achieved HBsAg seroclearance (0.33% annual seroclearance rate) and were included in this study. Results Baseline alanine aminotransferase (ALT) level >5 times of upper limit of normal was associated with higher probability of HBsAg seroclearance (HR 1.80, p<0.01), while HBeAg positivity (HR 0.46, p<0.01), high HBV DNA level (log10 IU/mL; HR 0.61, p<0.01), and cirrhosis (HR 0.48, p<0.01) were inversely associated with the probability of HBsAg seroclearance by multivariable analysis. During follow-up for 287 patient-years after HBsAg seroclearance, only two patients with baseline cirrhosis developed hepatocellular carcinoma (HCC) or died (0.7% annual risk), which was of a significantly lower rate compared with propensity score-matched patients without HBsAg seroclearance (HR 0.09, p<0.01). HBsAg reversion and/or HBV DNA reversion occurred in 18 patients, most of which were transient with extremely low serum levels of HBsAg (0.05-1.00 IU/mL) and HBV DNA (17-1818 IU/mL). None required retreatment. The cumulative probability of anti-HBs seroconversion (detection of anti-HBs) at 4 years was 67.4% by Kaplan-Meier analysis. Selection for lamivudine-resistance HBV mutants during treatment was not associated with composite reversion ( p=0.66). Conclusions HBsAg seroclearance achieved after NUC treatment was associated with favourable clinical outcomes and was durable in most cases during longterm follow-up. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.title | HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | An, Ji hyun | - |
dc.identifier.doi | 10.1136/gutjnl-2013-305517 | - |
dc.identifier.scopusid | 2-s2.0-84904042319 | - |
dc.identifier.wosid | 000339164200018 | - |
dc.identifier.bibliographicCitation | GUT, v.63, no.8, pp.1325 - 1332 | - |
dc.relation.isPartOf | GUT | - |
dc.citation.title | GUT | - |
dc.citation.volume | 63 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1325 | - |
dc.citation.endPage | 1332 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SURFACE-ANTIGEN QUANTIFICATION | - |
dc.subject.keywordPlus | SERUM HBSAG | - |
dc.subject.keywordPlus | VIRUS GENOTYPE | - |
dc.subject.keywordPlus | LAMIVUDINE THERAPY | - |
dc.subject.keywordPlus | DELAYED CLEARANCE | - |
dc.subject.keywordPlus | NEGATIVE PATIENTS | - |
dc.subject.keywordPlus | CHRONIC CARRIERS | - |
dc.subject.keywordPlus | SUSTAINED HBEAG | - |
dc.subject.keywordPlus | HIGH-RATES | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.identifier.url | https://gut.bmj.com/content/63/8/1325 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.